Cargando…

Benefits of SGLT2 inhibitors in arrhythmias

Some studies have shown that sodium-glucose cotransporter (SGLT) 2 inhibitors can definitively attenuate the occurrence of cardiovascular diseases such as heart failure (HF), dilated cardiomyopathy (DCM), and myocardial infarction. With the development of research, SGLT2 inhibitors can also reduce t...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Jinghan, Xue, Genlong, Zhan, Ge, Wang, Xinying, Li, Jiatian, Yang, Xiaolei, Xia, Yunlong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631490/
https://www.ncbi.nlm.nih.gov/pubmed/36337862
http://dx.doi.org/10.3389/fcvm.2022.1011429
_version_ 1784823829592276992
author Gao, Jinghan
Xue, Genlong
Zhan, Ge
Wang, Xinying
Li, Jiatian
Yang, Xiaolei
Xia, Yunlong
author_facet Gao, Jinghan
Xue, Genlong
Zhan, Ge
Wang, Xinying
Li, Jiatian
Yang, Xiaolei
Xia, Yunlong
author_sort Gao, Jinghan
collection PubMed
description Some studies have shown that sodium-glucose cotransporter (SGLT) 2 inhibitors can definitively attenuate the occurrence of cardiovascular diseases such as heart failure (HF), dilated cardiomyopathy (DCM), and myocardial infarction. With the development of research, SGLT2 inhibitors can also reduce the risk of arrhythmias. So in this review, how SGLT2 inhibitors play a role in reducing the risk of arrhythmia from the perspective of electrical remodeling and structural remodeling are explored and then the possible mechanisms are discussed. Specifically, we focus on the role of SGLT2 inhibitors in Na(+) and Ca(2 +) homeostasis and the transients of Na(+) and Ca(2 +), which could affect electrical remodeling and then lead to arrythmia. We also discuss the protective role of SGLT2 inhibitors in structural remodeling from the perspective of fibrosis, inflammation, oxidative stress, and apoptosis. Ultimately, it is clear that SGLT2 inhibitors have significant benefits on cardiovascular diseases such as HF, myocardial hypertrophy and myocardial infarction. It can be expected that SGLT2 inhibitors can reduce the risk of arrhythmia.
format Online
Article
Text
id pubmed-9631490
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96314902022-11-04 Benefits of SGLT2 inhibitors in arrhythmias Gao, Jinghan Xue, Genlong Zhan, Ge Wang, Xinying Li, Jiatian Yang, Xiaolei Xia, Yunlong Front Cardiovasc Med Cardiovascular Medicine Some studies have shown that sodium-glucose cotransporter (SGLT) 2 inhibitors can definitively attenuate the occurrence of cardiovascular diseases such as heart failure (HF), dilated cardiomyopathy (DCM), and myocardial infarction. With the development of research, SGLT2 inhibitors can also reduce the risk of arrhythmias. So in this review, how SGLT2 inhibitors play a role in reducing the risk of arrhythmia from the perspective of electrical remodeling and structural remodeling are explored and then the possible mechanisms are discussed. Specifically, we focus on the role of SGLT2 inhibitors in Na(+) and Ca(2 +) homeostasis and the transients of Na(+) and Ca(2 +), which could affect electrical remodeling and then lead to arrythmia. We also discuss the protective role of SGLT2 inhibitors in structural remodeling from the perspective of fibrosis, inflammation, oxidative stress, and apoptosis. Ultimately, it is clear that SGLT2 inhibitors have significant benefits on cardiovascular diseases such as HF, myocardial hypertrophy and myocardial infarction. It can be expected that SGLT2 inhibitors can reduce the risk of arrhythmia. Frontiers Media S.A. 2022-10-20 /pmc/articles/PMC9631490/ /pubmed/36337862 http://dx.doi.org/10.3389/fcvm.2022.1011429 Text en Copyright © 2022 Gao, Xue, Zhan, Wang, Li, Yang and Xia. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Gao, Jinghan
Xue, Genlong
Zhan, Ge
Wang, Xinying
Li, Jiatian
Yang, Xiaolei
Xia, Yunlong
Benefits of SGLT2 inhibitors in arrhythmias
title Benefits of SGLT2 inhibitors in arrhythmias
title_full Benefits of SGLT2 inhibitors in arrhythmias
title_fullStr Benefits of SGLT2 inhibitors in arrhythmias
title_full_unstemmed Benefits of SGLT2 inhibitors in arrhythmias
title_short Benefits of SGLT2 inhibitors in arrhythmias
title_sort benefits of sglt2 inhibitors in arrhythmias
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631490/
https://www.ncbi.nlm.nih.gov/pubmed/36337862
http://dx.doi.org/10.3389/fcvm.2022.1011429
work_keys_str_mv AT gaojinghan benefitsofsglt2inhibitorsinarrhythmias
AT xuegenlong benefitsofsglt2inhibitorsinarrhythmias
AT zhange benefitsofsglt2inhibitorsinarrhythmias
AT wangxinying benefitsofsglt2inhibitorsinarrhythmias
AT lijiatian benefitsofsglt2inhibitorsinarrhythmias
AT yangxiaolei benefitsofsglt2inhibitorsinarrhythmias
AT xiayunlong benefitsofsglt2inhibitorsinarrhythmias